In November 2018, the United Kingdom government made a significant change to drug scheduling. It allowed specialist doctors to prescribe cannabis-based products for medicinal use. For many patients with chronic conditions, this felt like a watershed moment. However, the reality of access has been far more nuanced than many headlines suggested. Today, I want to talk about how telehealth platforms and digital infrastructure in the UK have become the primary vehicles for accessing these treatments.
As someone who spent nine years working within https://newsroompanama.com/2026/05/27/inside-the-uks-medical-cannabis-boom-what-medical-cannabis-means-for-people/ the National Health Service (NHS)—the UK’s publicly funded healthcare system—I have seen firsthand how rigid administrative pathways can prevent patients from accessing specialized care. When medical cannabis was legalized, the NHS was, and remains, incredibly cautious. This caution created a significant gap in the market, which has been filled by private clinics operating almost entirely through digital channels.
The 2018 Shift and the NHS Prescribing Limit
Before we go any further, it is important to clarify a distinction. When we talk about medical cannabis in the UK, we are not talking about recreational use. We are talking about highly regulated, pharmaceutical-grade products. These are not the same as CBD (Cannabidiol) oil you might buy on the high street. CBD is a non-psychoactive compound found in cannabis, often sold as a wellness supplement, but it is entirely separate from the prescription-only medical cannabis flowers or oils regulated by the Home Office.
Following the 2018 law change, the National Institute for Health and Care Excellence (NICE) issued strict guidelines. They recommended that cannabis-based medicinal products (CBMPs) should only be prescribed in very narrow circumstances, such as severe treatment-resistant epilepsy or certain types of spasticity in multiple sclerosis. Because of these strict guidelines, most NHS consultants are hesitant to prescribe. They are not "anti-cannabis"; they are simply following the evidence-based protocols they are required to uphold.
This leaves thousands of patients with chronic pain, anxiety, or nerve damage stuck. They have failed two or more conventional treatments, yet they fall outside the narrow NHS criteria. This is where private clinics enter the picture.
The Rise of Private Telehealth Platforms
In the last five years, we have seen a surge in private medical cannabis clinics. These clinics rarely operate out of high-street offices. Instead, they rely on digital infrastructure and telehealth platforms to provide remote consultations. This model has been essential for patient access, especially for those living in rural areas who cannot easily travel to a specialist in London or Manchester.
Remote consultations allow a specialist doctor to assess a patient's history, review their Summary Care Record (SCR)—which is a secure summary of a patient's NHS medical record—and determine if they are eligible for a private prescription. By utilizing secure telehealth platforms, these clinics can maintain GDPR (General Data Protection Regulation) compliance while keeping administrative costs lower than traditional brick-and-mortar practices.
The Comparison: NHS vs. Private Access
Feature NHS Pathway Private Telehealth Pathway Availability Highly restricted Accessible for eligible conditions Cost Free at point of service Requires paid consultation + medication fees Speed Often months for referrals Usually 1–3 weeks for initial consult Infrastructure Standard NHS digital systems Dedicated telehealth platformsHow the Digital Workflow Actually Works
If you are a patient considering this route, it helps to understand the digital-first healthcare workflow. It is not just a video call. It is a structured medical process designed to ensure safety and clinical oversight.
Referral/Registration: You register with a clinic, often providing your NHS number. Records Review: The clinic requests your medical history from your GP (General Practitioner). This is a crucial step that many patients underestimate. If your records are incomplete, the process stalls. Remote Consultation: You have a video consultation with a specialist doctor. They will assess your symptoms and previous treatment failures. MDT Review: The doctor presents your case to an MDT (Multidisciplinary Team). This ensures that another specialist agrees with the prescribing plan. Prescription: If approved, the electronic prescription is sent to a specialized pharmacy. Delivery: The medication is sent via tracked courier directly to your door.Here is what usually happens next: The pharmacy will contact you to confirm payment and delivery details. Because this is a controlled drug, someone must be home to sign for the package. Do not expect it to be a "next-day delivery" situation; secure logistics take time.
Things Patients Wish They Knew Before the First Video Consult
In my interviews with patients, a few themes keep coming up. These are the things I wish someone had told me before I started navigating digital health pathways:
- Be prepared to be disappointed: Not everyone is eligible. These are specialist medicines, not a cure-all. If a clinic promises you a "miracle relief," that is a red flag. Turn around and leave. Have your medical history ready: You need to know exactly which medications you have tried, the doses, and why they failed (e.g., side effects or lack of efficacy). Test your tech: It sounds basic, but ensure your video and microphone are working. A bad connection makes a stressful medical conversation even harder. The "GP hurdle" is real: Some GPs are skeptical of private medical cannabis. They may refuse to share your records or may refuse to assist with "shared care" arrangements. You need to be prepared to manage that relationship. Cost is ongoing: It is not just the cost of the first consult. You will need follow-up appointments every few months to review your prescription, and that adds up.
The Role of Digital Infrastructure in Patient Safety
Why do we rely so heavily on these telehealth platforms? Beyond convenience, digital infrastructure in the UK allows for better monitoring of controlled substances. Through the patient portal, you can often track your prescription status, message your clinician, and upload symptom diaries. This data is vital. If a treatment isn't working, the doctor needs to know, and the digital portal is the most efficient way to communicate those trends.
However, we must remain critical of the industry. The digital-first model has allowed some clinics to scale very quickly. Rapid growth can sometimes lead to administrative errors. As a patient, you are a consumer in this private market, which means you have the right to ask for a clear explanation of fees, the background of your prescribing doctor, and the contingency plan if your medication is out of stock.
The Reality of Treatment
When you speak to patients, the stories are rarely about "miracle" outcomes. They are about small, incremental improvements: being able to sleep through the night, a reduction in the severity of neuropathic pain, or simply feeling more present. These are the markers of success that matter. If anyone tells you that medical cannabis is a "miracle," they are likely trying to sell you something. Effective medicine is rarely a miracle; it is a long, often boring process of trial, error, and consistent monitoring.
Remote consultations have made access possible for thousands who were previously ignored. They have moved the conversation from the margins into the mainstream digital health space. Yet, we still have a long way to go. We need better integration between private clinics and the NHS to ensure that patient records are shared seamlessly and that care is coordinated, not fragmented.
Final Thoughts
If you are exploring medical cannabis, approach it with the same caution you would any other specialist medical intervention. Use the telehealth platforms to find qualified specialists, check their GMC (General Medical Council) registration status, and be realistic about the process. The digital shift has opened a door, but the path beyond that door is still being paved.
The UK’s approach to medical cannabis will continue to evolve. As the evidence base grows, I hope to see the NHS adopt a more standardized approach, reducing the burden on private, out-of-pocket costs. Until then, stay informed, keep your documentation organized, and always prioritize your clinical safety over the convenience of a quick digital fix.